Melphalan in multiple myeloma.
Melphalan in multiple myeloma.
复制标题
马法兰在多发性骨髓瘤中的应用。
DOI：
10.1182/blood.v30.1.74.74
复制
发表时间：
1967
期刊：
影响因子：
20.3
通讯作者：
J. Holland
中科院分区：
文献类型：
--
作者：
B. Hoogstraten;P. Sheehe;J. Cuttner;T. Cooper;R. Kyle;R. Oberfield;S. R. Townsend;J. Harley;D. M. Hayes;G. Costa;J. Holland
1.一组64例骨髓瘤患者给予负荷剂量的美法仑，0.15 mg/kg。公斤/ Dx7随后是休息期，以使骨髓恢复，之后维持治疗，最大剂量为0.05 mg。公斤/ D开始了。2.为了获得良好的结果，需要产生显著骨髓抑制的药物剂量。3.约65%的患者主观症状改善，78%的患者客观症状改善。55%的患者有本研究中定义的反应。5.男性和女性之间的生存率没有差异，也没有发现本琼斯蛋白尿患者和那些没有。6.已经接受治疗3个月，然后被发现是反应者的患者比被归类为无反应者的类似治疗的患者寿命更长。
1. A group of 64 myeloma patients was given a loading dose of Melphalan, 0.15 mg./Kg./Dx7. This was followed by a rest period to allow bone marrow recovery to occur, after which maintenance therapy with a maximum of 0.05 mg./Kg./D was started. 2. To obtain good results, drug doses were required which produced significant bone marrow depression. 3. Subjective improvement was noticed in about 65 per cent of patients; objective improvement, in 78 per cent. 4. Fifty-five per cent of the patients had a response as defined in this study. 5. No difference in survival was found between males and females, nor between patients with Bence Jones proteinuria and those without. 6. Patients who have been on treatment for 3 months and were then found to be responders lived longer than similarly treated patients classified as nonresponders.